Clinical Trials Browser

Phase 3 × Neurotoxicity Syndromes × xaliproden × Clear all

NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Phase 3 Completed

Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

NCT00272051 2006-09-13

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Phase 3 Completed

Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes